Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions

Claim 3

The method of claim 1, wherein (a) the carbohydrate portion of said ganglioside derivatives has the structure (Gal)(GalNAC)(Gal)(Glc)(Ceramide) where Gal is a galactose moiety, GalNAC is an N-acetylgalactosamine moiety and Glc is a glucose moiety.

Claim 4

The method of claim 2, wherein (a) said ganglioside derivative has at least one N-acetyl-neuraminic acid bonded to at least one of said Gal moieties.

Claim 5

The method of claim 1, wherein (a) at least one of said ganglioside derivatives has the structure ##STR5## where Gal is a galactose moiety, GalNAC is an N-acetylgalactosamine moiety, Glc is a glucose moiety and NANA is an N-acetylneuraminic acid moiety, and wherein (b) said NANA is ester bonded to said Gal.

Claim 6

The method of claim 1, wherein said acid moiety, consists of N-acetyl-neuraminic acid.

Claim 7

The method of claim 1, wherein the carbohydrate portion consist of galactose, glucose and N-acetylgalactosamine moieties.

Claim 8

The method of claim 1, wherein said ganglioside derivative comprises a mixture of: ##STR6## wherein Gal represents a galactose moiety, GalNAC represents an N-acetylgalactosamine moiety, Glc represents a glucose moiety and NANA represents an N-acetyl-neuraminic moiety, and wherein at least one of said NANA moieties is ester bonded to a hydroxy group of a galactose moiety and/or an adjoining NANA moiety to form a lactonic ring.

Claim 9

A pharmaceutical composition for stimulating nerve sprouting which comprises a pharmaceutically acceptable carrier or diluent and an effective nerve sprouting stimulating amount of at least one inner ester ganglioside derivative comprising: (a) a carbohydrate portion, at least one ceramide and at least one acid moiety; (b) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (c) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuraminic acid; and (d) the carboxyl group of at least one of said acid moieties being ester bonded to a hydroxy group of one of said carbohydrates or one of said acid moieties to form a lactonic ring.

Claim 10

A pharmaceutical composition for stimulating nerve sprouting which comprises a pharmaceutically acceptable carrier or diluent and an effective nerve sprouting stimulating amount of at least one inner ester ganglioside derivative comprising: (a) a carbohydrate portion, at least one ceramide and at least one acid moiety; (b) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (c) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuraminic acid; and (d) the carboxyl group of at least one of said acid moieties being ester bonded to a hydroxy group of one of said carbohydrates or one of said acid moieties to form a lactonic ring.

Claim 11

The pharmaceutical composition of claim 8 in the form of an injectable solution.

Claim 12

The pharmaceutical composition of claim 8, wherein said carrier or diluent is a mixture of sodium chloride and a citrate buffer.

Claim 13

The pharmaceutical composition of claim 8, wherein said ganglioside derivative is present in an amount of from about 2% to about 50% by weight.

Claim 14

A pharmaceutical composition system for stimulating nerve sprouting which comprises a first container containing a solvent system and a second container containing a solid excipient and a lyophilized powder of an effective nerve sprouting stimulating amount of at least one inner ester ganglioside derivative, said ganglioside derivative comprising: (a) a carbohydrate portion, at least one ceramide and at least one acid moiety; (b) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (c) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuraminic acid; and (d) the carboxyl group of at least one of said acid moieties being ester bonded to a hydroxy group of one of said carbohydrates or one of said acid moieties to form a lactonic ring, whereby the contents of said containers are mixed to form a treatment solution.

Claim 15

A pharmaceutical composition system for stimulating nerve sprouting which comprises a first container containing a solvent system and a second container containing a solid excipient and a lyophilized powder of an effective nerve sprouting stimulating amount of at least one inner ester ganglioside derivative, said ganglioside derivative comprising: (a) a carbohydrate portion, at least one ceramide and at least one acid moiety; (b) said carbohydrate portion including at least one N-acetylgalactosamine or N-acetylglucosamine moiety and at least one glucose or galactose moiety; (c) said acid moiety including at least one N-acetylneuraminic acid or N-glycolylneuraminic acid; and (d) the carboxyl group of at least one of said acid moieties being ester bonded to a hydroxy group of one of said carbohydrates or one of said acid moieties to form a lactonic ring, whereby the contents of said containers are mixed to form a treatment solution.

Claim 16

The pharmaceutical composition system of claim 12, wherein said first container contains sodium chloride and a citrate buffer.

Claim 17

The pharmaceutical composition system of claim 12, wherein said solid excipient is glycine.

Claim 18

The pharmaceutical composition system of claim 12, wherein said solid excipient is mannitol.

Claim 19

The pharmaceutical composition system of claim 12, wherein said second container contains said ganglioside derivative in an amount of from about 10% to about 90% by weight.

Claim 20

The pharmaceutical composition of claim 8, wherein (a) the carbohydrate portion of said ganglioside derivatives has the structure (Gal)(GalNAC)(Gal)(Glc)(Ceramide) where Gal is a galactose moiety, GalNAC is an N-acetylgalactosamine moiety and Glc is a glucose moiety.

Claim 21

A pharmaceutical composition as in claim 24, wherein (a) said ganglioside derivative has at least one N-acetylneuraminic acid bonded to at least one of said Gal moieties.

Claim 22

A pharmaceutical composition as in claim 8, wherein (a) at least one of said ganglioside derivatives has the structure ##STR7## Where Gal is a galactose moiety, GalNAC is an N-acetylgalactosamine moiety, Glc is a glucose moiety and NANA is an N-acetylneuraminic acid moiety, and wherein (b) said NANA is ester bonded to said Gal.

Claim 23

The pharmaceutical composition of claim 8, wherein said acid moiety consists of N-acetyl-neuraminic acid, and the carbohydrate portion consists of galactose, glucose and N-acetylgalactosamine moieties.

Claim 24

The pharmaceutical composition of claim 8, wherein said ganglioside derivative comprises a mixture of: ##STR8## wherein Gal represents a galactose moiety, GalNAC represents an N-acetylgalactosamine moiety, Glc represents a glucose moiety and NANA represents an N-acetyl-neuraminic moiety, and wherein at least one of said NANA moieties is ester bonded to a hydroxy group of a galactose moiety and/or an adjoining NANA moiety to form a lactonic ring.